Mostrar el registro sencillo del ítem
| dc.creator | Sanmartí Sala, Raimon | |
| dc.creator | Graell, Eduard | |
| dc.creator | Pérez, María L. | |
| dc.creator | Ercilla González, M. Guadalupe | |
| dc.creator | Viñas, Odette | |
| dc.creator | Gómez-Puerta, José Alfredo | |
| dc.creator | Gratacós Masmitjà, Jordi | |
| dc.creator | Balsa, Alejandro | |
| dc.creator | Gómara Elena, María José | |
| dc.creator | Larrosa, Marta | |
| dc.creator | Cañete Crespillo, Juan D. | |
| dc.creator | Haro Villar, Isabel | |
| dc.date | 2010-11-19T11:30:09Z | |
| dc.date | 2010-11-19T11:30:09Z | |
| dc.date | 2009-09-02 | |
| dc.date.accessioned | 2024-12-16T10:25:33Z | |
| dc.date.available | 2024-12-16T10:25:33Z | |
| dc.identifier | 1478-6362 | |
| dc.identifier | http://hdl.handle.net/2445/14462 | |
| dc.identifier | 19725967 | |
| dc.identifier.uri | http://fima-docencia.ub.edu:8080/xmlui/handle/123456789/19619 | |
| dc.description | Introduction: Evidence suggests that citrullinated fibrin(ogen) may be a potential in vivo target of anticitrullinated protein/peptide antibodies (ACPA) in rheumatoid arthritis (RA). We compared the diagnostic yield of three enzyme-linked immunosorbent assay (ELISA) tests by using chimeric fibrin/filaggrin citrullinated synthetic peptides (CFFCP1, CFFCP2, CFFCP3) with a commercial CCP2-based test in RA and analyzed their prognostic values in early RA. Methods: Samples from 307 blood donors and patients with RA (322), psoriatic arthritis (133), systemic lupus erythematosus (119), and hepatitis C infection (84) were assayed by using CFFCP- and CCP2-based tests. Autoantibodies also were analyzed at baseline and during a 2-year follow-up in 98 early RA patients to determine their prognostic value. Results: With cutoffs giving 98% specificity for RA versus blood donors, the sensitivity was 72.1% for CFFCP1, 78.0% for CFFCP2, 71.4% for CFFCP3, and 73.9% for CCP2, with positive predictive values greater than 97% in all cases. CFFCP sensitivity in RA increased to 80.4% without losing specificity when positivity was considered as any positive anti-CFFCP status. Specificity of the three CFFCP tests versus other rheumatic populations was high (> 90%) and similar to those for the CCP2. In early RA, CFFCP1 best identified patients with a poor radiographic outcome. Radiographic progression was faster in the small subgroup of CCP2-negative and CFFCP1-positive patients than in those negative for both autoantibodies. CFFCP antibodies decreased after 1 year, but without any correlation with changes in disease activity. Conclusions: CFFCP-based assays are highly sensitive and specific for RA. Early RA patients with anti-CFFCP1 antibodies, including CCP2-negative patients, show greater radiographic progression. | |
| dc.format | 9 p. | |
| dc.format | application/pdf | |
| dc.language | eng | |
| dc.publisher | BioMed Central | |
| dc.relation | Reproducció del document publicat a http://dx.doi.org/10.1186/ar2802 | |
| dc.relation | Arthritis Research and Therapy, 2009, 11:R135 | |
| dc.relation | http://dx.doi.org/10.1186/ar2802 | |
| dc.rights | cc-by, (c) Sanmarti et al., 2009 | |
| dc.rights | http://creativecommons.org/licenses/by/2.0/ | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.source | Articles publicats en revistes (Medicina) | |
| dc.subject | Artritis reumatoide | |
| dc.subject | Diagnòstic | |
| dc.subject | Rheumatoid arthritis | |
| dc.subject | Diagnosis | |
| dc.title | Diagnostic and prognostic value of antibodies against chimeric fibrin/filaggrin citrullinated synthetic peptides in rheumatoid arthritis | |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:eu-repo/semantics/publishedVersion |
| Ficheros | Tamaño | Formato | Ver |
|---|---|---|---|
|
No hay ficheros asociados a este ítem. |
|||